Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: SYRE 1 – 5 MRNA Matrix Metrics: SYRE 4 – 6 MRNA

As of Nov 16, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas MRNA carries 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs MRNA
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.35β · 101% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.4 · SMA20: $230.06 · SMA50: $203.13

6-Pillar Scorecard Institutional Category Breakdown (SYRE 1 – 5 MRNA)

Columns: Metric · SYRE · MRNA
1. Valuation Multiples MRNA
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M N/M
EV / Revenue N/M 38.3x
2. Growth & Scale MRNA
Revenue Growth (YoY) +0.0% +29.2%
Earnings Growth (YoY) -99.7% -85.1%
TTM Revenue (USD) N/A $2.52B
Market Cap $9.8B $93.6B
3. Profitability & Quality SYRE
Gross Margin N/A -42.0%
Operating Margin 0.0% -80.8%
Net Profit Margin 0.0% -110.5%
Return on Equity (ROE) -35.0% -34.5%
4. Balance Sheet & Cash Flow MRNA
Cash Generation (TTM) N/A -$2.04B
Cash Flow Margin N/A -81.0%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 87.9% (10th %ile) 70.5% (30th %ile)
Put/Call OI Skew N/A 1.12x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity N/A 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (4) vs MRNA (6)
Institutional Metric SYRE MRNA Criterion Row Edge
Market Capitalization
Scale
$9.8B $93.6B Larger Scale MRNA
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+0.0% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
0.0% -80.8% Higher Margin SYRE
Net Profit Margin
Profitability
0.0% -110.5% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-35.0% -34.5% Higher ROE MRNA
52-Week Range Position
Momentum
88% ($22–$111) 75% ($22–$281) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 2.35β · 101% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 46.8 / 100 (HOLD) Higher Composite MRNA
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 38.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +26.05 pp
SYRE: +25.11% · MRNA: -0.94%
3M Horizon MRNA +250.29 pp
SYRE: -7.29% · MRNA: +243.0%
6M Horizon MRNA +306.24 pp
SYRE: +42.64% · MRNA: +348.88%
1Y Horizon MRNA +423.46 pp
SYRE: +341.74% · MRNA: +765.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MRNA. Trailing 12-month operating profitability (SYRE 0.0% vs MRNA -80.8%) and valuation multiples (SYRE N/M vs MRNA 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
18d in phase · OBV NEUTRAL
Current IV 70.5%
IV Percentile 30th %ile
Put/Call OI Skew 1.12x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $93.6B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ SYRE vs MRNA Key Questions & Quantitative Answers

As of Nov 16, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas MRNA carries 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin). Technically, SYRE sits in a Neutral phase (RSI 56.6, UNCLASSIFIED options structure) and MRNA sits in a Neutral phase (RSI 48.4, CONSOLIDATION options structure).

MRNA leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $2.52B for MRNA. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

MRNA screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 38.3x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, MRNA carries 70.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 1.12x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.35β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.